Hepatocellular Carcinoma advanced-stage hepatocellular carcinoma, unresectable hepatocellular carcinoma
Conditions
Interventions
None listed
Sponsors
Suzuki Yuji
Takikawa Yasuhiro
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with BCLC stage B or C unresectable hepatocellular carcinoma who are not eligible for local therapy. Patients who are receiving a new molecularly targeted drug such as sorafenib or lenvatinib will be eligible for the study. Other patients participating in clinical trials of molecularly targeted drugs being conducted will also be eligible.
Exclusion criteria
Exclusion criteria: Any of the following 1) to 4) 1) Patients who have been informed by themselves or their representatives that they will not participate in the research. 2) Patients who are deemed unsuitable for inclusion in the study by the attending physician. 3) Patients whose mutant genes were not identified in next-generation sequencing analysis of primary tissues. 4) Patients with no next of kin to obtain final consent for pathology at the time of death.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate assessed by mRECIST on CT and MRI at 2 months after the start of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival and overall survival as assessed by mRECIST on CT and MRI two months after the start of treatment. | — |
Contacts
Public ContactYuji Suzuki
Iwate Medical University
Outcome results
None listed